Publication

Accuracy of the new rapid test for monitoring adalimumab levels

View document

Bibliographic Details
Summary:The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples.
Main Authors:Rocha, C
Other Authors:Afonso, J; Lago, P; Arroja, B; Vieira, AI; Dias, CC; Magro, F
Subject:Adalimumab
Year:2019
Country:Portugal
Document type:article
Access type:open access
Associated institution:Hospital de Braga
Language:English
Origin:Repositório Científico do Hospital de Braga

Similar Items

Similar Items